Advertisement

Advertisement

SOHO 2019

Leukemia

Asciminib/Imatinib in Patients With Previously Treated CML

In a phase I trial, the combination of the BCR-ABL1 inhibitor asciminib and the small-molecule kinase inhibitor imatinib showed preliminary efficacy, safety, and tolerability in patients with chronic...

inrebic
jakafi

SOHO 2019: Fedratinib in Patients With Myelofibrosis: JAKARTA Trials Update

In analyses reported at the 2019 Society of Hematologic Oncology (SOHO) Annual Meeting and published in Clinical Lymphoma, Myeloma & Leukemia, Harrison et al identified response rates to the JAK2 ...

darzalex
decadron
pomalyst

SOHO 2019: Melflufen for Patients With Late-Stage, Relapsed or Refractory Multiple Myeloma Refractory to Daratumumab and/or Pomalidomide

In a presentation of updated efficacy and safety data from the phase II HORIZON trial, Paul G. Richardson, MD, and colleagues found that melflufen, a lipophilic peptide-conjugated alkylator, showed a...

Leukemia

SOHO 2019: Asciminib/Imatinib in Patients With Previously Treated CML

In a phase I trial, the combination of the BCR-ABL1 inhibitor asciminib and the small-molecule kinase inhibitor imatinib showed preliminary efficacy, safety, and tolerability in patients with chronic ...

Advertisement

Advertisement



Advertisement